Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
Timeline of Regulatory Milestones 2005: Exenatide (Byetta): First GLP-1 agonist approved, twice-daily injections 2010: Liraglutide (Victoza): Longer-lasting, once-daily injection 2014: Dulaglutide (Trulicity): Once-weekly injection arrives 2017: Semaglutide (Ozempic): First once-weekly injection for diabetes with powerful weight-loss effects 2019: Oral semaglutide (Rybelsus): First GLP-1 pill makes it past the stomachs defenses 2021: High-dose semaglutide (Wegovy): FDA approval for obesity treatment 2022: Tirzepatide (Mounjaro): First dual GLP-1/GIP agonist for diabetes 2023: Tirzepatide (Zepbound): Expanded approval for obesity 20232024 : Widespread shortages: Skyrocketing demand for GLP-1s leads to limited availability The shortage that began in late-2023, driven by soaring off-label demand and supply-chain bottlenecks left millions of patients unable to fill even maintenance scripts
Add GLP-1-Boosting supplements: Incorporate HUMs Flatter Me Fiber GLP-1 Booster into your daily habits
The company said the study demonstrated significant and clinically meaningful weight loss over 48 weeks, supporting plans to advance the program into Phase III development
Holistic Support for Your Wellbeing: Essential vitamins and minerals contribute to a strong immune system and overall health, while promoting a radiant glow
2022;102:1S127
US$ 21.20
US$ 23.08
US$ 21.76
US$ 21.45
